Skip to main content

Table 1 (abstract A.57). Change from baseline in monthly average migraine days during 12-weeks of double-blind treatment by sex and age groupa

From: 13th European Headache Federation Congress 2019: Meeting Abstracts - part 2

  Placebo Monthly fremanezumab Quarterly fremanezumab
Males (n = 46) (n = 45) (n = 47)
 LSM (SE) change −0.4 (0.74) −4.6 (0.78) −4.2 (0.73)
 LSMD (SE) vs placebo −4.2 (0.91)b − 3.8 (0.87)b
Females (n = 232) (n = 238) (n = 229)
 LSM (SE) change −0.6 (0.35) −3.9 (0.34) −3.6 (0.35)
 LSMD (SE) vs placebo −3.3 (0.39)b − 3.0 (0.39)b
Age 18–45 years (n = 120) (n = 128) (n = 125)
 LSM (SE) change −0.8 (0.47) −4.6 (0.49) −4.1 (0.48)
 LSMD (SE) vs placebo −3.8 (0.51)b − 3.2 (0.51)b
Age > 45 years (n = 158) (n = 155) (n = 151)
 LSM (SE) change −0.4 (0.48) −3.8 (0.47) −3.6 (0.49)
 LSMD (SE) vs placebo −3.4 (0.50)b − 3.2 (0.51)b
  1. LSM least-squares mean, LSMD LSM difference
  2. aModified ITT population (n = 837)
  3. bP < 0.0001 vs placebo
\